Skip to main content
Drug bottle and Pill

Compare Uptravi vs. Adempas

Head-to-head comparisons of medication uses, side effects, warnings, and more.

Key takeaways

Uptravi (selexipag) and Adempas (riociguat) are both medications used to treat pulmonary arterial hypertension (PAH), but they have some key differences. Uptravi is a prostacyclin agonist that works by relaxing the blood vessels in your lungs, and it is taken twice a day either orally or through an IV. In contrast, Adempas is a soluble guanylate cyclase (sGC) stimulator that also relaxes blood vessels but is taken every 8 hours and is only available in tablet form. Adempas is also used to treat chronic thromboembolic pulmonary hypertension (CTEPH), while Uptravi is not. Adempas has a significant risk of causing severe harm to unborn babies, so it is only available to females through a special REMS program, whereas Uptravi does not have this restriction. Common side effects for Uptravi include headache, diarrhea, and nausea, while Adempas also commonly causes a headache as well as indigestion, and dizziness. Additionally, Adempas can cause severe bleeding and dangerously low blood pressure, which are less common with Uptravi.

Browse medications

View All

Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.